Discover our latest insights. 

PHM has been redefining cancer care for nearly two decades – ensuring our clients receive cutting-edge treatments, advanced diagnostics, and personalized guidance. Our newly released whitepaper, “Improving Cancer Survival: PHM’s Impact on Cancer Care,” is grounded in 15 years of data. Our clients with advanced cancer survived 2 to 4 times longer than patients in the NCI.

Clinical trials are pivotal in advancing cancer treatment and improving patient outcomes. They offer patients access to cutting-edge treatments while contributing valuable insights that drive the evolution of cancer care. This whitepaper examines clinical trials as a potential value lever within employer-sponsored health plans, highlighting their dual impact on enhancing cancer care and managing healthcare costs.

Pancreatic cancer is notoriously difficult to treat. At PHM we deploy comprehensive molecular profiling to identify potential treatment options for all patients with cancer. Along with our partners at Guardant Health, we …

Ovarian cancers are the second most common cancer of the female reproductive system and are associated with the highest risk of cancer-related death, with most women presenting with advanced-stage disease. A recent …

PHM, a clinically sophisticated healthcare navigation firm specializing in serious and complex conditions, reveals a significant gap in the provision of cutting-edge cancer diagnostics and treatments within the U.S. employer population. PHM’s …

Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide. Despite decades of research and multiple treatment options including chemo and hormone therapies, many patients still experience worsening disease and develop metastatic castration-resistant prostate cancer (mCRPC), which is typically fatal. Providing these patients with access to improved treatments may help them to survive longer and improve their quality of life. PHM’s research has been published in the peer-reviewed publication “Frontiers in Oncology.” In this case report, we summarize the treatment course for a 73-year-old male patient, who came to PHM for assistance in managing his mCRPC.